267 related articles for article (PubMed ID: 22357167)
1. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
2. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A
Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Poyurovsky M; Weizman R; Weizman A
Am J Psychiatry; 2008 Mar; 165(3):398; author reply 398-9. PubMed ID: 18316435
[No Abstract] [Full Text] [Related]
6. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
Narita M; Takei D; Shiokawa M; Tsurukawa Y; Matsushima Y; Nakamura A; Takagi S; Asato M; Ikegami D; Narita M; Amano T; Niikura K; Hashimoto K; Kuzumaki N; Suzuki T
Eur J Pharmacol; 2008 Dec; 600(1-3):105-9. PubMed ID: 18955042
[TBL] [Abstract][Full Text] [Related]
7. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
[TBL] [Abstract][Full Text] [Related]
8. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
9. Tardive dyskinesia due to aripiprazole: report of 2 cases.
Lungu C; Aia PG; Shih LC; Esper CD; Factor SA; Tarsy D
J Clin Psychopharmacol; 2009 Apr; 29(2):185-6. PubMed ID: 19512985
[No Abstract] [Full Text] [Related]
10. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
11. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
12. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
13. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
[TBL] [Abstract][Full Text] [Related]
14. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
15. Reversal of symptomatic hyperprolactinemia by aripiprazole.
Wahl R; Ostroff R
Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
[No Abstract] [Full Text] [Related]
16. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Keck PE; McElroy SL
Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
[TBL] [Abstract][Full Text] [Related]
17. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen.
Evcimen YA; Evcimen H; Holland J
Am J Psychiatry; 2007 Sep; 164(9):1436-7. PubMed ID: 17728431
[No Abstract] [Full Text] [Related]
19. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Crismon ML; DeLeon A; Miller AL
Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
[No Abstract] [Full Text] [Related]
20. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
